CRSP vs EDIT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRSP and EDIT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRSP and EDIT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

Full CRSP guide

Editas Medicine (EDIT) is a clinical-stage biotechnology company developing gene-editing medicines based on CRISPR technology. It aims to treat serious diseases by making precise changes to DNA, and has shifted its strategy toward in vivo genomic medicines, which edit genes directly inside the body, after earlier work on ex vivo cell therapies. Its lead program, EDIT-401, is an experimental in vivo therapy aimed at lowering cholesterol-related risk. On October 8, 2026 Editas received approval in Australia to begin Strive, a Phase 1/2 first-in-human trial in patients with heterozygous familial hypercholesterolemia, with dosing expected to begin in 2026 and initial safety data in the first quarter of 2027. Editas is unprofitable and pre-commercial: it has no approved products and generates only modest revenue, mostly from licensing its intellectual property, while spending heavily on research and burning cash each quarter. Cash stood at roughly $124 million at the end of March 2026, when the company projected a runway into the third quarter of 2027, and had risen to ~$212 million by June 30, 2026, per Yahoo Finance data, alongside workforce reductions (to about 87 employees) meant to focus spending on its lead programs. Trailing twelve-month revenue is ~$47 million and the trailing net loss ~$74 million. As of October 16, 2026 the stock closed near $2.40, up ~17% year to date and down ~39% over one year, and the next quarterly report is expected around November 9. Headquartered in Cambridge, Massachusetts, Editas is a highly speculative, science-stage company whose value depends almost entirely on unproven clinical results, financing, and the broader competition to turn CRISPR editing into approved therapies. Nothing here is investment advice.

Full EDIT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.
• EDIT drivers: CRISPR gene-editing platform; Focus on in vivo medicines and EDIT-401.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $13.4 million over the twelve months to June 2026. For EDIT, editas is a highly speculative, clinical-stage biotech with no approved products and no meaningful product revenue, and it loses money and burns cash every quarter.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CRSP if you believe its drivers more; EDIT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRSP and EDIT guides.

CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based multiples like P/E are negative and not analytically useful; the company is better evaluated on cash runway, Casgevy adoption, and the risk-adjusted value of its pipeline. Market cap of about $4.9 billion less roughly $1.6 billion of net cash leaves an enterprise value near $3.3 billion, which reflects significant execution uncertainty. Targets remain widely spread, from UBS at $52 to a consensus mean near $86.

EDIT. Editas cannot be valued on normal earnings measures because it is pre-commercial and unprofitable, so metrics like P/E do not apply. At ~$369 million, its market value sits not far above its ~$212 million of mid-2026 cash, so the market is assigning modest value to the pipeline and CRISPR intellectual property ahead of the first human EDIT-401 data in early 2027. Cash runway matters because an unprofitable biotech that runs low on cash typically must raise money by issuing new shares, which dilutes existing holders. All figures are approximate, are drawn from a fast-changing clinical-stage company, and can change quickly; verify current numbers before relying on them.

Headline figures (approximate, October 2026): CRSP shows revenue (ttm to jun 30, 2026) ~$13.4 million (Q2 2026 ~$10.2 million), revenue (full year 2025) ~$3.5 million, net loss (ttm) ~$451 million; Q2 2026 ~$91 million, eps (q2 2026, actual vs estimate) -$0.94 vs -$1.18; EDIT shows stage clinical-stage, pre-commercial (no approved products), profitability unprofitable; TTM net loss ~$74 million and ongoing cash burn, revenue (ttm) ~$47 million, mainly licensing and collaboration (Q2 2026 ~$11.9M), net loss (q2 2026) ~$18 million; EPS -$0.15 vs -$0.28 estimate.

CRSP and EDIT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRSP and EDIT exposure against your real portfolio. It is not an investment adviser.